Document Detail

Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure.
MedLine Citation:
PMID:  9784909     Owner:  NLM     Status:  MEDLINE    
Carnitine is an important cofactor in the intermediary metabolism of the heart, and carnitine deficiency is associated with congestive heart failure. We therefore studied the effects of acute (IV bolus, 30 mg/kg body weight) and chronic administration (1.5 mg/d for 1 month) of propionyl-L-carnitine on hemodynamics, hormone levels, ventricular function, exercise capacity, and peak oxygen consumption in 30 patients with chronic congestive heart failure (NYHA II-III, mean EF 29.5 +/- 7%) in a phase II, parallel, single-blind, randomized, and placebo-controlled study. Acute administration of propionyl-L-carnitine caused a significant reduction in pulmonary artery and pulmonary wedge pressures at both day 1 (P < 0.001) and day 30 (P < 0.05) of the study but no other hemodynamics changes. Hormone levels did not change following acute administration of the drug. Chronic administration of propionyl-L-carnitine increased peak oxygen consumption by 45% (from 16.0 +/- 3 to 23.5 +/- 2 mL/kg/min, P +/- 0.001), exercise time by 21% (from 8.1 +/- 0.5 to 9.8 +/- 0.4 minutes, P < 0.01), and peak exercise heart rate by 12% (P < 0.01). These changes were concomitant with a reduction of pulmonary artery pressure. In the treated group, there was a slight, but significant (P < 0.01), reduction in left ventricular dimensions. Hemodynamics and hormones measured after 1 month of oral therapy remained unchanged, except for a fall in pulmonary artery pressures, with a nonsignificant trend towards a fall in filling pressures and plasma norepinephrine. The chronic changes in the propionyl-L-carnitine group were seen at 15 days of treatment, and no further changes in these parameters were seen at 1 month. We conclude that propionyl-L-carnitine increases exercise capacity and reduces ventricular size in patients with congestive heart failure. The drug has no significant effects on hemodynamics or neurohormone levels. The use of a single-blind design reduces the impact of the positive finding on exercise capacity.
I Anand; Y Chandrashekhan; F De Giuli; E Pasini; A Mazzoletti; R Confortini; R Ferrari
Related Documents :
9935029 - Chronotropic competence in endurance trained heart transplant recipients: heart rate is...
1704529 - Pr interval behavior during exercise: implications for physiological pacemakers.
17165639 - Understanding the basics of cardiopulmonary exercise testing.
3552299 - Why patients with heart failure die: hemodynamic and functional determinants of survival.
19837829 - Determinants of postexercise heart rate recovery in patients with the obstructive sleep...
8376689 - Exercise rehabilitation in chronic heart failure.
10694119 - Plasma creatine kinase responses of 18- to 30-yr-old african-american men to eccentric ...
21884579 - Rebranding exercise: closing the gap between values and behavior.
2706029 - Aerobic fitness in patients with fibrositis. a controlled study of respiratory gas exch...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  12     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1998 Jul 
Date Detail:
Created Date:  1998-12-30     Completed Date:  1998-12-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  291-9     Citation Subset:  IM    
VA Medical Center, Minneapolis, Minnesota, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiotonic Agents / therapeutic use*
Carnitine / analogs & derivatives*,  therapeutic use
Exercise Tolerance / drug effects*
Heart Failure / drug therapy*,  physiopathology
Hemodynamics / drug effects*
Hormones / blood*
Middle Aged
Neurosecretory Systems / physiology
Oxygen Consumption / drug effects
Single-Blind Method
Time Factors
Ventricular Function
Reg. No./Substance:
0/Cardiotonic Agents; 0/Hormones; 17298-37-2/propionylcarnitine; 541-15-1/Carnitine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of verapamil on heart rate variability after an acute myocardial infarction. Danish Verapamil...
Next Document:  A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from...